International Journal of Internal Medicine

Objective To analyze the application of azithromycin combined with methylprednisolone in the treatment of severe mycoplasma pneumonia in children. Methods A total of 70 children with severe mycoplasma pneumonia in our hospital from January 2021 to January 2022 were selected. The digital table was randomly divided into 2 groups with 35 cases in each group. The patients in the control group were treated with azithromycin. nylon. The improvement time of cough and other clinical manifestations, inflammatory factors, total effective rate, and adverse reactions were compared between the two groups before and after treatment. Results The body temperature of the observation group returned to normal, the cough symptoms disappeared, the lung rales disappeared, and the hospitalization time was (6.33±2.36) d, (10.05±2.12) d, (7.01±1.91) d, and (11.12±2.07) d, respectively. Shorter than the control group (7.71±2.81) d, (12.13±3.34) d, (12.45±2.33) d, (14.71±2.21) d, P<0.05. The comparison of inflammatory factors in the two groups before treatment, P>0.05, and after treatment, the inflammatory factors in both groups were improved, and the inflammatory factors in the observation group were significantly lower than those in the control group, P<0.05. The total effective rate of the observation group was higher than that of the control group, P<0.05. There were no serious adverse reactions in both groups, P>0.05. Conclusion Azithromycin combined with methylprednisolone is effective and safe in the treatment of severe mycoplasma pneumonia in children.

Azithromycin; Methylprednisolone; Severe mycoplasma pneumonia in children; Application